



## **Predictive Biosciences Announces Patent Issuance for Multiple Biomarker Assay**

**LEXINGTON, MA – June 16, 2011** – Predictive Biosciences, a provider of novel molecular diagnostic tests, announced that on June 7, 2011 the U.S. Patent and Trademark Office issued Patent Number 7,955,822 for "Detection of Nucleic Acids and Proteins". The patent supports the Company's core multiple biomarker technology for molecular testing.

The patent focuses on methods for detecting target nucleic acids and proteins in a single assay. Predictive Biosciences utilizes these methods in its Multi-Analyte Diagnostic Readout (MADR)<sup>™</sup> approach, by combining the sensitivity of protein biomarkers with the inherent specificity of DNA biomarkers to determine disease state.

"The diagnostic world is moving towards combining multiple analytes like DNA, RNA, protein, and metabolites to maximize clinical performance. However, with currently available technologies, these various analyte types must be measured with separate analytical procedures. Our approach allows us to combine the benefits of DNA and protein biomarkers together in a single assay which could be run on a variety of PCR-based platforms," said Anthony Shuber, Chief Technology Officer. "The issuance of this patent is a significant achievement for Predictive Biosciences as we continue to build a strong IP foundation for our company's products."

Predictive Biosciences has a portfolio of innovative cancer assays which include the CertNDx<sup>™</sup> Molecular Grading Assay, a tissue based test that provides definitive diagnostic and prognostic information for bladder cancer detection, and the CertNDx<sup>™</sup> Bladder Cancer Assay for hematuria assessment that identifies patients with bladder cancer.

### **About Predictive Biosciences**

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays and a urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. For additional information, please visit [www.predictivebiosci.com](http://www.predictivebiosci.com).

### **For more information:**

Sharon Martin

Predictive Biosciences

(781) 402-1780 x246

[smartin@predictivebiosci.com](mailto:smartin@predictivebiosci.com)

#